Welcome to our dedicated page for Lisata Therapeutics news (Ticker: LSTA), a resource for investors and traders seeking the latest updates and insights on Lisata Therapeutics stock.
Lisata Therapeutics, Inc. develops investigational therapies for advanced solid tumors and other serious diseases. Its principal product candidate, certepetide, is a proprietary iRGD cyclic peptide designed to activate an uptake pathway that can improve tumor targeting and penetration by co-administered or tethered anti-cancer agents.
Recurring Lisata news covers clinical and preclinical data involving certepetide, collaborations and license agreements tied to antibody-drug conjugates and other delivery technologies, development-rights changes for regional markets, financial results, business updates, and corporate matters affecting governance or capital structure.
BASKING RIDGE, N.J., Nov. 7, 2022 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) announced participation in key upcoming events. These include the RNA at the Bench and Bedside III from November 8-10 in Carlsbad, CA, with David Slack attending one-on-one meetings. They will also present at the Inv€$tival Showcase 2022 on November 14 in London, with David J. Mazzo presenting a corporate overview at 2:30 p.m. GMT. Lastly, management will engage in one-on-one meetings at the Jefferies London Healthcare Conference from November 15-17, also in London.
Lisata Therapeutics, a clinical-stage pharmaceutical company, will announce its financial results for Q3 2022 on November 10, 2022, at 4:30 p.m. (ET). The company is focused on developing therapies for advanced solid tumors. Its lead product, LSTA1, aims to enhance the delivery of anti-cancer drugs by modifying the tumor microenvironment. Clinical trials have shown LSTA1 to be safe and effective for pancreatic cancer treatment. Lisata’s technology platform also supports autologous CD34+ cell therapy programs.
Lisata Therapeutics (Nasdaq: LSTA) announced its participation in two significant events: the RNA USA Leaders Congress on October 18-19, 2022, where David S. Slack will join a keynote panel, and the LD Micro Main Event XV Conference on October 25-27, 2022, featuring a presentation by CEO David J. Mazzo. Lisata is focused on developing therapies for advanced solid tumors, with its lead candidate LSTA1 showing promise in enhancing chemotherapy delivery for pancreatic cancer. The company also investigates other therapies through its CD34+ cell technology platform.
Lisata Therapeutics (Nasdaq: LSTA) announced that Erkki Ruoslahti, M.D., Ph.D., has received the 2022 Albert Lasker Basic Medical Research Award. Recognized for his discovery of integrins, Ruoslahti's work underpins the CendR Platform™, which enhances drug delivery to solid tumors. The CendR platform is central to Lisata's lead clinical program, LSTA1, targeting advanced solid tumors. Ruoslahti's accolades highlight significant contributions to medical science, including over 150 patents. Lisata focuses on developing therapies for challenging cancers, leveraging Ruoslahti's expertise.